Amarin Corporation plc · NASDAQ:AMRN
Amarin — Amarin Corp Plc\uk — Investor Presentation (January 2022)
24 slides from Amarin's investor presentation, Jan 10, 2022
Slide 1: Investor Presentation January 2022
Investor Presentation JANUARY 2022 a new paradigm in preventative cardiovascular care Exhibit 99.2
Slide 2: Forward Looking Statements & Disclaimer
Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, generic pr
Slide 3: Vision: to stop heart disease from being a leading cause of death
VISION... ...to stop heart disease from being a leading cause of death For 30 years, the focus has been on lowering LDL cholesterol. Statins have reduced LDL with success and still serve a critical purpose, but they are not the complete solution. Elevated triglycerides are also an important marker t
Slide 4: Cardiovascular Disease Is an Enormous and Worsening Public Health Burden
EVERY 36 SECONDS in the US1 ~60M with CVD in Europe4 523M living with CVD globally6 $1.1tn Estimated economic burden by 20352 €210BN annual spending on CV disease management4 ~18M CVD deaths globally in 20196 44M patients Are projected to be on statins3 >4M People die each year from CVD in the Europ
Slide 5: Placebo groups show high persistent CV risk despite statins
Placebo groups from multiple recent trials show high P-CVR despite statin-based standard-of-care; 14.6% to 34.7% of patients treated for LDL-C, but not for P-CVR, experienced a major adverse cardiovascular event (MACE) in 3-7 Years. Years of follow up All statin-treated patients had well controlled
Slide 6: CV drug development: a challenging endeavor
CV drug development: A CHALLENGING endeavor SUCCEEDING in a challenging environment Many biopharma abandoned drug development in CV Requirements for long-term outcomes studies evaluating thousands of patients take years to fulfill With REDUCE-IT®, developed the first and only approved medication for
Slide 7: VASCEPA/VAZKEPA Demonstrated CV Risk Reduction Beyond Standard-of-Care
VASCEPA/VAZKEPA has Demonstrated CV Risk Reduction Beyond Standard-of-Care (including Statins) in Landmark CVOT HR = hazard ratio; NNT = number needed to treat 1. Bhatt DL et al; for REDUCE-IT® Investigators. N Engl J Med. 2019;380(1):11-22 HR = 0.80 (95% CI, 0.66-0.98) P=0.03 CV Death 20% RRR HR =
Slide 8: VASCEPA/VAZKEPA Has the Lowest NNT Among New Therapies
VASCEPA/VAZKEPA Has the Lowest NNT Among New Therapies Proven to Reduce MACE When Added to Current Standard-of-Care Statin monotherapy On top of statin therapy *Based on primary composite endpoints of each trial Note: Cross-trial comparisons are subject to differences in populations, primary outcome
Slide 9: A Preventative Cardiovascular Care Treatment Option Beyond LDL-C Lowering
VASCEPA/VAZKEPA is a Preventative Cardiovascular (CV) Care Treatment Option Beyond LDL-C Lowering VASCEPA/VAZKEPA is the only drug proven to reduce persistent CV risk in the population studied (P-CVR) Pre-Statin Statin Before 1987 Modest LDL-C or HDL-C 1987 and beyond Aggressive LDL-C “Lower is Bett
Slide 10: Broad Third-Party Support for Icosapent Ethyl
Broad Third-Party Support for Icosapent Ethyl American Association of Clinical Endocrinologists Chinese Society of Cardiology Brazilian Society of Cardiology American College of Endocrinology American College of Cardiology American Diabetes Association American Heart Association American Stroke Asso
Slide 11: Expanding to Europe and International
Before 2021; Mostly R&D and US Commercial Focus 2021 and Beyond: Expanding to Europe and International US EUROPE INTERNATIONAL APPROVED Approved for lowering cardiovascular risk (2019) and treating severe hypertriglyceridemia (original niche indication – 2012) APPROVED for lowering cardiovascular ri
Slide 12: Amarin Future Growth Strategy
Amarin Future Growth Strategy AMARIN
Slide 13: Full Year 2021 Financial Highlights
Full Year 2021 Financial Highlights Total full year 2021 revenue, net expected to approximate $580 million (unaudited), compared with $614.1 million in 2020 U.S. VASCEPA retained 80% and 86% of the IPE market, as per Symphony Health data in the three months and eleven months ended November 30, 2021,
Slide 14: Amarin go-to-market
Amarin go-to-market Expanding Healthcare Provider Engagement: 3-4 X amplification of physicians reach through digital channels Sales force optimization to focus on the most productive and accessible territories Managed Care Access Enhancement: Drive incremental volume growth through further removing
Slide 15: Early signals of the impact of our new Go-To-Market Strategy
Early signals of the impact of our new Go-To-Market Strategy New to Brand (NTB) growth being led by Branded VASCEPA– Up 8% in recent 4 weeks reaching pre-generic level – Total IPE up 5% Cardiology, Primary Care and Endocrinology all contributing to NTB growth Importantly, Cardiology showing consiste
Slide 16: VAZKEPA in Europe
VAZKEPA in Europe December 2020 Regulatory approval No Reimbursement None Infrastructure None Medical Education Limited Supply Chain Solid manufacturing network & 3PL agreement Marketing Strategy Initial Planning Team Recruitment of core team ~10 December 2021 EMA & MHRA 10 market dossiers submitted
Slide 17: Europe Outlook 2022
Europe Outlook 2022: Filed market access dossiers in ten key EU countries ahead of YE schedule Reimbursement decisions expected in up to 8 countries The launch of VAZKEPA in up to 6 countries Plans to file next wave of five market access dossiers in 2022 Execution of several agreements in Central &
Slide 18: Launched VAZKEPA in Germany
Launched VAZKEPA in Germany Relentless focus on education, awareness & access World class scientific launch, scientific media resonance and recognition (Galenus von Pergamon prize finalist) Short Pre-Launch and Covid resurgence, leading to an average frequency of 2.6 in our targeted doctors VAZKEPA
Slide 19: Partnering to Unlock Revenue Potential in ~20 Additional Markets
Partnering to Unlock Revenue Potential in ~20 Additional Markets Internationally EU US sNDA Approved Dec. 20191,2 China / HK MENA Approved in Lebanon (Mar. 2018), UAE (Jul. 2018), Qatar (Jan. 2020), Bahrain (Nov. 2020) Mexico Russia Australia Brazil Japan India Direct launch Partnered Unpartnere
Slide 20: Plans to Bring VASCEPA/VAZKEPA to 20 Additional Markets
Note: The company is pursuing expansion into these various additional markets and the status of regulatory and/or patent approval will vary between market to market. Plans to Bring Unique Cardioprotective Benefits of VASCEPA/VAZKEPA to 20 Additional Markets 1st Wave 2022 2nd Wave 2023 Supported by R
Slide 21: VASCEPA/VAZKEPA Life Cycle Management Progress
VASCEPA/VAZKEPA Life Cycle Management Progress AS A RESULT OF THE LCM EFFORT to enhance our offering to patient in need of reducing their Cardiovascular Risk And in-line with our cardiovascular outcome label where icosapent ethyl is used on top of a statin AMARIN IS INITIATING the development of a f
Slide 22: Amarin Strengthens its Executive and Board Leadership
Amarin Strengthens its Executive and Board Leadership: 4 New Executive Members Laurent Abuaf Senior Vice President & President of Europe August 2021 Jason Marks Chief Legal Officer & Corporate Secretary August 2021 Alan Wills Executive Vice President Corporate Business Development November 2021 Lisa
Slide 23: Amarin: An Exciting Opportunity to Create Value
Amarin: An Exciting Opportunity to Create Value US EUROPE FUTURE INTERNATIONAL Grow and defend VASCEPA despite generics’ presence on the market for the VHTG indication Advance the Go-to-Market digital omnichannel model to drive greater awareness and demand Development of fixed dose combination – ico
Slide 24: Investor Presentation JANUARY 2022
Investor Presentation JANUARY 2022
Amarin Corp Plc\uk — Investor Presentation (January 2022) on 6ix